Istari Oncology, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Durham NC United States (2014)

Organization Overview

First Clinical Trial
2018
NCT03564782
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Istari Oncology, Inc.

Active Ingredients

Drugs in Phase 2 Trials (5)

atezolizumab (Tecentriq) (2 trials)

lerapolturev (2 trials)

lomustine (1 trial)

pembrolizumab (keytruda) (1 trial)

pvsripo (8 trials)

Drugs in Phase 1 Trials (2)

d2c7 (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 7